Home・Listă Acțiuni・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Închisă

SectorSănătate

48.27 3.07

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

47.63

Maxim

48.36

Indicatori cheie
By Trading Economics
Venit	-56M -58M
Vânzări	11M 219M
EPS	0.39
Marjă de profit	-26.646
Angajați	778
EBITDA	-50M -30M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+35.07% upside

Dividende
By Acuity
Următoarele câștiguri	3 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	9.3M 2.7B
Deschiderea anterioară	45.2
Închiderea anterioară	48.27

Sentimentul știrilor

By Acuity

50%

142 / 340 Clasament în Healthcare

Supernus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 aug. 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 aug. 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 aug. 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 aug. 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 aug. 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 aug. 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 aug. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 aug. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 aug. 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 aug. 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 iul. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 iul. 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

29 iul. 2026, 17:26 UTC

Supernus Pharmaceuticals Inc. shares are lower today amid volatility, with no specific news identified. The stock remains below its 20-day moving average.

28 iul. 2026, 17:06 UTC

Supernus Pharmaceuticals Inc. shares are higher today, recovering from an earlier decline. The stock remains near the lower end of its one-month trading range.

27 iul. 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares are higher Monday, despite earlier gains pulling back. Market dynamics reflect a significant decline in oil prices and inflation reassessment.

24 iul. 2026, 19:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, following an early peak, amid broader market dynamics influenced by a pullback in crude oil prices.

20 iul. 2026, 20:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early high amid a broader market decline during the session.

Comparație

Modificare preț

Supernus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

35.07% sus

Prognoză pe 12 luni

Medie 65.2 USD 35.07%

Maxim 67 USD

Minim 63 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSupernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Supernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

142 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.